Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: Evidence for an endocannabinoid tone in the human neocortex

Neuroscience

Volumn 120, Issue 2, 2003, Pages 455-465

  Steffens, M ^a   Szabo, B ^b   Klar, M ^a   Rominger, A ^a   Zentner, J ^a   Feuerstein, T J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acetylcholine release; CB1 cannabinoid receptor; Endocannabinoid; Human neocortex; SR141716; WIN55212 2

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; O 1184; RIMONABANT; TRITIUM; UNCLASSIFIED DRUG; 6' AZIDOHEX 2' YNE DELTA(8) TETRAHYDROCANNABINOL; 6'-AZIDOHEX-2'-YNE-DELTA(8)-TETRAHYDROCANNABINOL; ACETYLCHOLINE; ARACHIDONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR; CHOLINE; DRUG DERIVATIVE; DRUG RECEPTOR; ENDOCANNABINOID; HEMICHOLINIUM 3; MORPHOLINE DERIVATIVE; N (4 HYDROXYPHENYL)ARACHIDONYLAMIDE; N-(4-HYDROXYPHENYL)ARACHIDONYLAMIDE; NAPHTHALENE DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COGNITION; DRUG EFFECT; ELECTROSTIMULATION; EVOKED CORTICAL RESPONSE; HUMAN; HUMAN TISSUE; MOUSE; NEOCORTEX; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; ADOLESCENT; ADULT; ANIMAL; BINDING COMPETITION; BRAIN LEVEL; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ACETYLCHOLINE; ADOLESCENT; ADULT; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CALCIUM CHANNEL BLOCKERS; CHILD; CHOLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENDOCANNABINOIDS; HEMICHOLINIUM 3; HUMANS; MICE; MIDDLE AGED; MORPHOLINES; NAPHTHALENES; NEOCORTEX; NOOTROPIC AGENTS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL; TRITIUM;

EID: 0141923483     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00318-X     Document Type: Article

References (58)

1. 3H]-acetylcholine release in rat and human neocortex. Exp Brain Res. 128:1999;383-389.
2. Axelrod J., Felder C.C. Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem Res. 23:1998;575-581.
3. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 evidence for a new model of receptor/ligand interactions . J Biol Chem. 272:1997;22330-22339.
4. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 60:2001;155-163.
5. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci. 654:1992;33-51.
6. Coutts A.A., Brewster N., Ingram T., Razdan R.K., Pertwee R.G. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol. 129:2000;645-652.
7. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptor Channels. 1:1993;121-134.
8. Devane W.A., Dysarz F.A. 3rd, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:1988;605-613.
9. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
10. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties biochemistry and possible physiopathological relevance . Biochim Biophys Acta. 1392:1998;153-175.
11. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain . J Neurochem. 75:2000;2434-2444.
12. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 99:2002;10819-10824.
13. Feuerstein T.J., Dooley D.J., Seeger W. Inhibition of norepinephrine and acetylcholine release from human neocortex by ω-conotoxin GVIA. J Pharmacol Exp Ther. 252:1990;778-785.
14. 1-Opioid receptor-mediated control of acetylcholine (ACh) release in human neocortex slices. Int J Dev Neurosci. 16:1998;795-802.
15. 2-autoreceptor in human neocortex. J Pharmacol Exp Ther. 294:2000;356-362.
16. Feuerstein T.J., Limberger N. Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn Schmiedebergs Arch Pharmacol. 359:1999;345-359.
17. Furchgott, RF (1972) The classification of adrenoceptors (adrenergic receptors): an evaluation from the standpoint of receptor theory. In: Handbook of experimental pharmacology, pp 283-335. Berlin: Springer.
18. Gifford A.N., Ashby C.R. Jr. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A. J Pharmacol Exp Ther. 277:1996;1431-1436.
19. Giuffrida A., Rodriguez de Fonseca F., Nava F., Loubet-Lescoulie P., Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol. 408:2000;161-168.
20. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neurosci. 106:2001;1-4.
21. Hampson A.J., Bornheim L.M., Scanziani M., Yost C.S., Gray A.T., Hansen B.M., Leonoudakis D.J., Bickler P.E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem. 70:1998;671-676.
22. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Ric K.C. Characterization and localization of cannabinoid receptors in rat brain a quantitative in vitro audioradiographic study . J Neurosci. 11:1991;563-583.
23. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 29:1986;307-313.
24. Huang C.C., Lo S.W., Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol. 532:2001;731-748.
25. Jehle T., Bauer J., Blauth E., Hummel A., Darstein M., Freiman T.M., Feuerstein T.J. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol. 130:2000;1227-1234.
26. Kathmann M., Weber B., Schlicker E. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn Schmiedebergs Arch Pharmacol. 363:2001;50-56.
27. Katona I., Sperlagh B., Magloczky Z., Santha E., Kofalvi A., Czirjak S., Mackie K., Vizi E.S., Freund T.F. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience. 100:2000;797-804.
28. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. 21:2001;9506-9518.
29. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci. 21:2001;RC174.
30. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat implications for receptor-mediated immune modulation by cannabinoids . J Pharmacol Exp Ther. 268:1994;1612-1623.
31. Maejima T., Ohno-Shosaku T., Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci Res. 40:2001;205-210.
32. Malinowska B., Kwolek G., Göthert M. Anandamide and methanandamide induce both vanniloid VR1 and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthesized rats. Naunyn Schmiedebergs Arch Pharmacol. 364:2001;562-569.
33. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 327:1993;535-550.
34. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned DNA. Nature. 346:1990;561-564.
35. 3H-acetylcholine from rat cerebral cortex slices in vitro. Br J Pharmacol. 47:1973;97-108.
36. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
37. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
38. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptor. Pharmacol Ther. 74:1997;129-180.
39. Piomelli D., Giuffrida A., Calignano A., Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. 21:2000;218-224.
40. Richardson I.W., Szerb J.C. The release of labelled acetylcholine and choline from cerebral cortical slices stimulated electrically. Br J Pharmacol. 52:1974;499-507.
41. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubri P., Breliere J.C., Le Fur G. Biochemical characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
42. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
43. Schlicker E., Timm J., Zentner J., Göthert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;583-589.
44. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 22:2001;565-572.
45. + M-current in hippocampal CA1 neurons. J Neurosci. 20:2000;51-58.
46. Singer E.A. Transmitter release from brain slices elicited by single pulses a powerful method to study presynaptic mechanisms . Trends Pharmacol Sci. 9:1988;274-276.
47. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
48. Sullivan J.M. Mechanisms of cannabinoid-receptor mediated inhibition on synaptic transmission in cultured hippocampal pyramidal neurons. J Neurophysiol. 82:1999;1286-1294.
49. Sullivan J.M. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem. 7:2000;132-139.
50. Szabo B., Dorner L., Pfreundtner C., Norenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
51. Szabo B., Wallmichrath I., Mathonia P., Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neurosci. 97:2000;89-97.
52. Szabo B., Wallmichrath I. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience. 113:2002;671-682.
53. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
54. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 78:1997;43-50.
55. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
56. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia loss of neurons in the basal forebrain . Science. 215:1982;1237-1239.
57. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592.
58. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 31:2001;453-462.